MX2019007840A - Celulas asesinas naturales modificadas geneticamente. - Google Patents
Celulas asesinas naturales modificadas geneticamente.Info
- Publication number
- MX2019007840A MX2019007840A MX2019007840A MX2019007840A MX2019007840A MX 2019007840 A MX2019007840 A MX 2019007840A MX 2019007840 A MX2019007840 A MX 2019007840A MX 2019007840 A MX2019007840 A MX 2019007840A MX 2019007840 A MX2019007840 A MX 2019007840A
- Authority
- MX
- Mexico
- Prior art keywords
- cells
- natural killer
- genetically modified
- killer cells
- modified natural
- Prior art date
Links
- 210000000822 natural killer cell Anatomy 0.000 title abstract 5
- 102100035273 E3 ubiquitin-protein ligase CBL-B Human genes 0.000 abstract 2
- 101000737265 Homo sapiens E3 ubiquitin-protein ligase CBL-B Proteins 0.000 abstract 2
- 101150069255 KLRC1 gene Proteins 0.000 abstract 2
- 101100404845 Macaca mulatta NKG2A gene Proteins 0.000 abstract 2
- 102100022682 NKG2-A/NKG2-B type II integral membrane protein Human genes 0.000 abstract 2
- 102000004060 Transforming Growth Factor-beta Type II Receptor Human genes 0.000 abstract 2
- 108010082684 Transforming Growth Factor-beta Type II Receptor Proteins 0.000 abstract 2
- 208000036142 Viral infection Diseases 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 244000052769 pathogen Species 0.000 abstract 1
- 230000001717 pathogenic effect Effects 0.000 abstract 1
- 230000035755 proliferation Effects 0.000 abstract 1
- 210000004881 tumor cell Anatomy 0.000 abstract 1
- 230000009385 viral infection Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0646—Natural killers cells [NK], NKT cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4613—Natural-killer cells [NK or NK-T]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464466—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/70—Enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Oncology (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Se proveen aqui células asesinas naturales (NK, por sus siglas en inglés) modificadas genéticamente (GM) y métodos de producción de poblaciones de células NK GM. Además, se proveen aquí métodos de uso de las células NK GM descritas en la presente. por ejemplo, para suprimir la proliferación de células tumorales, o para inhibir la infección de patógenos, por ejemplo. infección viral. En ciertas alternativas, las células NK GM aqui provistas carecen de expresión de CBLB, NKG2A y/o TGFBR2 y/o función. o muestran expresión y lo función reducida de CBLB. NKG2A y/o TGFBR2 En ciertas alternativas, las células NK GM aqui provistas comprenden CD16 modificada.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662440909P | 2016-12-30 | 2016-12-30 | |
PCT/US2017/068827 WO2018126074A1 (en) | 2016-12-30 | 2017-12-28 | Genetically modified natural killer cells |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2019007840A true MX2019007840A (es) | 2020-08-03 |
Family
ID=62711057
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2019007840A MX2019007840A (es) | 2016-12-30 | 2017-12-28 | Celulas asesinas naturales modificadas geneticamente. |
Country Status (10)
Country | Link |
---|---|
US (2) | US20180273903A1 (es) |
EP (1) | EP3562492A4 (es) |
JP (2) | JP2020503043A (es) |
CN (1) | CN110913870A (es) |
AU (1) | AU2017386790A1 (es) |
BR (1) | BR112019013282A2 (es) |
CA (1) | CA3048979A1 (es) |
EA (1) | EA201991607A1 (es) |
MX (1) | MX2019007840A (es) |
WO (1) | WO2018126074A1 (es) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2018265534A1 (en) * | 2017-05-11 | 2019-10-31 | Nantkwest, Inc. | Anti-EGFR/high affinity NK-cells compositions and methods for chordoma treatment |
KR20210013077A (ko) * | 2018-05-16 | 2021-02-03 | 더 리서치 인스티튜트 앳 네이션와이드 칠드런스 하스피탈 | Cas9 리보핵단백질을 사용하는 녹아웃 일차 및 확장된 인간 nk 세포의 생성 |
WO2020014245A1 (en) * | 2018-07-10 | 2020-01-16 | Nantkwest, Inc. | Cryopreservation |
CN109117403B (zh) * | 2018-07-17 | 2020-07-10 | 武汉精测电子集团股份有限公司 | 一种基于serdes电路产生c_phy信号的装置 |
WO2020168300A1 (en) * | 2019-02-15 | 2020-08-20 | Editas Medicine, Inc. | Modified natural killer (nk) cells for immunotherapy |
CN110079529A (zh) * | 2019-04-28 | 2019-08-02 | 成都美杰赛尔生物科技有限公司 | 用于靶向敲除人NKG2A/KLRC1基因的sgRNA、表达载体、试剂盒及其用途 |
AU2020288829A1 (en) * | 2019-06-04 | 2021-12-02 | Nkarta, Inc. | Combinations of engineered natural killer cells and engineered T cells for immunotherapy |
US20230355759A1 (en) * | 2019-07-31 | 2023-11-09 | Celularity Inc. | Populations of natural killer cells comprising a cleavage resistant cd16 |
CA3157344A1 (en) * | 2019-11-20 | 2021-05-27 | Cartherics Pty. Ltd. | Method for providing immune cells with enhanced function |
WO2021113849A1 (en) * | 2019-12-05 | 2021-06-10 | Celularity Inc. | Her2+ cancer treatment with populations of natural killer cells comprising a cleavage resistant cd16 |
WO2021252804A1 (en) | 2020-06-12 | 2021-12-16 | Nkarta, Inc. | Genetically modified natural killer cells for cd70-directed cancer immunotherapy |
CN116194125A (zh) * | 2020-08-07 | 2023-05-30 | 克莱格医学有限公司 | 工程化改造的细胞以及工程化改造细胞的方法 |
AU2021369476A1 (en) * | 2020-10-26 | 2023-06-08 | Shoreline Biosciences, Inc. | Methods of inducing antibody-dependent cellular cytotoxicity (adcc) using modified natural killer (nk) cells |
WO2022095902A1 (en) * | 2020-11-03 | 2022-05-12 | Hangzhou Qihan Biotechnology Co., Ltd. | Systems and methods for enhanced immunotherapies |
US11661459B2 (en) | 2020-12-03 | 2023-05-30 | Century Therapeutics, Inc. | Artificial cell death polypeptide for chimeric antigen receptor and uses thereof |
TW202241935A (zh) | 2020-12-18 | 2022-11-01 | 美商世紀治療股份有限公司 | 具有可調適受體專一性之嵌合抗原受體系統 |
WO2022226337A1 (en) * | 2021-04-22 | 2022-10-27 | Artec Biotech, Inc. | Method for producing hematopoietic cells from stem cells using vascular organoids |
IL311790A (en) * | 2021-10-05 | 2024-05-01 | Chang Hao Ming | Natural killer cells and methods of their use |
TW202325843A (zh) * | 2021-11-03 | 2023-07-01 | 中國大陸商杭州啟函生物科技有限公司 | 用於增強免疫療法的系統和方法 |
TW202325844A (zh) * | 2021-11-03 | 2023-07-01 | 中國大陸商杭州啟函生物科技有限公司 | 增強免疫療法的系統和方法 |
WO2023215278A1 (en) * | 2022-05-03 | 2023-11-09 | The Broad Institute, Inc. | Modified immune cells and methods for use thereof |
CN114921416B (zh) * | 2022-05-12 | 2023-05-23 | 广东普罗凯融生物医药科技有限公司 | 一种nk细胞及其制备方法 |
CN115820645B (zh) * | 2022-11-28 | 2023-09-22 | 上海恩凯细胞技术有限公司 | 制备沉默nkg2a基因的nk细胞的方法及其用途 |
CN116590237B (zh) * | 2023-05-29 | 2023-10-31 | 上海贝斯昂科生物科技有限公司 | 一种遗传修饰的自然杀伤细胞及其制备和用途 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101878034B (zh) * | 2007-09-28 | 2013-11-20 | 细胞基因细胞疗法公司 | 使用人胎盘灌洗液和人来自胎盘的中间体自然杀伤细胞的肿瘤抑制 |
WO2009046104A1 (en) * | 2007-10-01 | 2009-04-09 | University Of Miami | Aptamer-targeted sirna to prevent attenuation or suppression of t cell function |
AT506041A1 (de) * | 2007-12-10 | 2009-05-15 | Univ Innsbruck | Verfahren zur erhöhung der immunreaktivität |
US20110280849A1 (en) * | 2010-03-26 | 2011-11-17 | Anthrogenesis Corporation | Tumor suppression using human placenta-derived intermediate natural killer cells and immunomodulatory compounds |
EP2471548A1 (de) * | 2010-12-28 | 2012-07-04 | Apeiron Biologics AG | siRNA gegen Cbl-b und optional IL2 und IL12 zur Verwendung in der Behandlung von Krebs |
CA2881792C (en) * | 2012-08-13 | 2024-02-27 | Anthrogenesis Corporation | Natural killer cells and uses thereof |
US11311575B2 (en) * | 2013-05-13 | 2022-04-26 | Cellectis | Methods for engineering highly active T cell for immunotherapy |
EP3008173B1 (en) * | 2013-06-10 | 2021-09-15 | Dana-Farber Cancer Institute, Inc. | Methods and compositions for reducing immunosupression by tumor cells |
US10144770B2 (en) * | 2013-10-17 | 2018-12-04 | National University Of Singapore | Chimeric receptors and uses thereof in immune therapy |
EP4227318A1 (en) * | 2014-03-28 | 2023-08-16 | Regents of the University of Minnesota | Polypeptides, cells, and methods involving engineered cd16 |
SG11201608701QA (en) * | 2014-04-18 | 2016-11-29 | Editas Medicine Inc | Crispr-cas-related methods, compositions and components for cancer immunotherapy |
CN107106677A (zh) * | 2014-08-28 | 2017-08-29 | 莱顿大学学术医院以Lumc的名义运作 | Cd94/nkg2a和/或cd94/nkg2b抗体、疫苗组合 |
EA201791443A1 (ru) * | 2014-12-31 | 2018-01-31 | Антродженезис Корпорейшн | Естественные киллерные клетки и их применения |
-
2017
- 2017-12-28 MX MX2019007840A patent/MX2019007840A/es unknown
- 2017-12-28 JP JP2019535369A patent/JP2020503043A/ja active Pending
- 2017-12-28 WO PCT/US2017/068827 patent/WO2018126074A1/en active Application Filing
- 2017-12-28 CA CA3048979A patent/CA3048979A1/en active Pending
- 2017-12-28 BR BR112019013282A patent/BR112019013282A2/pt unknown
- 2017-12-28 EA EA201991607A patent/EA201991607A1/ru unknown
- 2017-12-28 AU AU2017386790A patent/AU2017386790A1/en not_active Abandoned
- 2017-12-28 US US15/857,516 patent/US20180273903A1/en not_active Abandoned
- 2017-12-28 EP EP17886775.0A patent/EP3562492A4/en active Pending
- 2017-12-28 CN CN201780087586.1A patent/CN110913870A/zh active Pending
-
2021
- 2021-12-17 US US17/645,004 patent/US20220348875A1/en active Pending
-
2022
- 2022-12-08 JP JP2022196025A patent/JP2023036648A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
CA3048979A1 (en) | 2018-07-05 |
WO2018126074A1 (en) | 2018-07-05 |
US20220348875A1 (en) | 2022-11-03 |
EP3562492A4 (en) | 2020-12-09 |
EP3562492A1 (en) | 2019-11-06 |
BR112019013282A2 (pt) | 2019-12-17 |
CN110913870A (zh) | 2020-03-24 |
US20180273903A1 (en) | 2018-09-27 |
EA201991607A1 (ru) | 2020-01-24 |
AU2017386790A1 (en) | 2019-07-18 |
JP2023036648A (ja) | 2023-03-14 |
JP2020503043A (ja) | 2020-01-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2019007840A (es) | Celulas asesinas naturales modificadas geneticamente. | |
MX2018004600A (es) | Celulas aniquiladoras naturales y células ilc3 y usos de las mismas. | |
PH12019501557A1 (en) | Bacillus isolates and uses thereof | |
EA201791443A1 (ru) | Естественные киллерные клетки и их применения | |
EP4219696A3 (en) | Oncolytic virus strain | |
MX2021002415A (es) | Celulas madre hematopoyeticas modificadas geneticamente y usos de las mismas. | |
WO2020096986A3 (en) | Selection of improved tumor reactive t-cells | |
MX2019002904A (es) | Composiciones de arn de alta pureza y métodos para su preparación. | |
AU2016262093A8 (en) | Enhancing endonuclease based gene editing in primary cells | |
MX2020010014A (es) | Celulas asesinas naturales y lineas de celulas asesinas naturales modificadas con aumento de la citotoxicidad. | |
WO2016201047A8 (en) | Crispr/cas-related methods and compositions for improving transplantation | |
EP4339287A3 (en) | Modified cells and methods of therapy | |
MX2018010924A (es) | Células efectoras inmunitarias con edición genómica. | |
PH12017500803A1 (en) | Anti-pd-1 antibodies | |
WO2018064594A3 (en) | Hla class i-deficient nk-92 cells with decreased immunogenicity | |
PH12020550039A1 (en) | Sialyltransferases and their use in producing sialylated oligosaccharides | |
WO2019035880A8 (en) | EXOSOMES OF PURIFIED MESENCHYMAL STEM CELLS AND USES THEREOF | |
MX2021005398A (es) | Terapia del cancer con celulas inmunitarias anti-cd33. | |
PH12021551241A1 (en) | Expansion of natural killer cells and ilc3 cells with novel aromatic compounds | |
MX2021009554A (es) | Produccion de virus en cultivos celulares. | |
WO2017048809A8 (en) | Nk cells exhibiting an adaptive phenotype and methods for preparing and for using | |
MX2021002220A (es) | Forma cristalina de base libre de lorlatinib. | |
PH12018500379A1 (en) | Biopharmaceutical compositions | |
MX2022001257A (es) | Composiciones y preparaciones de células nk para inmunoterapia y métodos para su producción. | |
MX2021014525A (es) | Adenovirus modificados. |